BOT.AU · Botanix Pharmaceuticals Limited

-

Please sign in to comment on BOT.AU

1 Comment

Admin

4 years, 11 months ago

Botanix Pharmaceuticals Limited is currently in a long term downtrend where the price is trading 19.6% below its 200 day moving average.

From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.

Botanix Pharmaceuticals Limited's total revenue sank by 14.4% to $89K since the same quarter in the previous year.

Its net income has increased by 109.5% to $664K since the same quarter in the previous year.

Finally, its free cash flow grew by 63.6% to $-3M since the same quarter in the previous year.

Based on the above factors, Botanix Pharmaceuticals Limited gets an overall score of 3/5.

Exchange	AU
ISIN	AU000000BOT2
Industry	Biotechnology
CurrencyCode	AUD
Sector	Healthcare

Target Price	0.4967
Beta	0.84
Market Cap	129M
PE Ratio	None
Dividend Yield	None

ABOUT

Botanix Pharmaceuticals Limited

Botanix Pharmaceuticals Limited operates as a commercial dermatology company in Australia and the United States. The company's lead product is Sofdra (sofpironium) topical gel, a prescription anticholinergic medicine used on the skin to treat underarm sweating in adults and children 9 years of age and older. Its product pipeline includes BTX 1503, a transdermal gel formulation for the treatment of serious acne in adults and teenagers; BTX 1801 for treating staphylococcus aureus and methicillin resistant staphylococcus aureus; BTX 1702 for the treatment of papulopustular rosacea; and BTX 1204A for treating atopic dermatitis. The company was incorporated in 1984 and is based in West Perth, Australia.

BOT.AU · Botanix Pharmaceuticals Limited

-

Botanix Pharmaceuticals Limited

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest Botanix Pharmaceuticals Limited using a moving average strategy